ANALYSI S ON SECONDARY I NFECTI ON- TRI GGERI NG MICROORGANISMS IN HIV/AIDS PATIENTS AS A MODEL FOR POLICY CONTROL
Downloads
HIV infection is associated with immune-compromised and rising in opportunistic infection (secondary infection). Therefore, the number of mortality caused by HIV/AIDS is increasing. The use of ARV and development of HIV/AIDS management are expected to suppress the progress of HIV infection into AIDS and, therefore, the mortality can be diminished, while in fact most of the patients eventually suffer from AIDS due to secondary infection that commonly causes death. There should be a management by analysing microorganisms that trigger secondary infection. The method of this study was observational descriptive with cross sectional design. HIV infected blood samples were using ELISA Antibody (IgG and IgM) and Polymerase Chain Reaction (PCR) on laboratory test. The result showed correlation between HIV/AIDS severity and the amount and types of secondary infection. The most common secondary infections were toxoplasm (96.77%), hepatitis C (22.58%), tuberculosis (19.35%), and hepatitis B (3.22%). Other less frequent secondary infections, which were quite difficult to diagnose and not commonly found in Indonesia, were West Nile Virus (25.81%), Japanese Encephalitis Virus (3.22%), and Enterovirus (3.22%). Due to MDGs (Millenium Development Goals) target and the results above, researchers are highly demanded to contribute in decreasing mortality related to AIDS through early detection of secondary infection,including type of infection which have not been commonly found in Indonesia, such as West Nile Virus and Nipah Virus. The discovery of secondary infection in this study was not enough to suppress the occurrence of infection in HIV/AIDS patients. Antimicrobes and good nutrition are required. Moreover, there should be either a primary or secondary prophylaxis to prevent secondary infection that raises the number of mortality and morbidity of HIV/AIDS patients. The result of this study was to meet the target of MDGs by establishing new policies in handling HIV/AIDS infections and have potential as model for policy control in HIV/AIDS.
Nasronudin. 2007. Penatalaksanaan Koinfeksi Penderita HIV. Dalam:
HIV & AIDS Pendekatan Biologi Molekuler, Klinis dan Sosial. Ed. Barakbah J, dkk. Surabaya, AUP, 177–183.
World Health Organization. 2010. Recommendation for HIV/ Tuberculosis Coinfection. In: Antiretroviral therapy for HIV infection in adults and adolescent: recommendation for a public health approach. Geneva, Switzerland, 58–63.
Kemenkes RI. 2011. Terapi ARV pada Koinfeksi Tuberculosis. Dalam: Pedoman Nasional Tata laksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa. Jakarta. Kementerian Kesehatan RI, 30–31.
Benson CA, Kaplan JE, Masur H, 2004. Treating opportunistic infections among HIV-exposed andinfected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR.
Sester M, Giehl C, McNerney R, Kampmann B, Walzl G, Cuchi P, Wingfield C, Lange C, 2010. Challenges and Perspectives for Improved Management of HIV/Mycobacterium Tuberculosis coinfection. Eur Respir J, 36, 1242–47.
Cakraborty N, 2008. Current Trends of Opportunistic Infection among HIV Seropositive Patients from Eastern India. Jpn. J Infect Dis, 61, 49–53.
Retnowati E, 2008. Koinfeksi HIV dan Hepatitis B Patogenesis dan Diagnosis. Dalam: Simposium Nasional Penyakit Tropik-Infeksi dan HIV&AIDS, Surabaya 22–23 Maret 2008, hlm. 149–156.
Amor Sandra, 2009. Manson's Tropical Diseases: Virus Infections of the Central Nervous Systems. Saunders Elsevier: China. p. 859–63.
Alter JM. 2011. Viral Hepatitis C. In: Tropical Infectious Diseases Principles, Pathogens & Practice. Edinburgh, p. 427–432.
Astari L, Sawitri, Yunia Eka Safitri. 2009. Viral Load pada Infeksi HIV. Available from http://journal.unair.ac.id/filerPDF/Viral.pdf
Heller HM. 2012. Toxoplasmosis in HIV Infected Patients. UpToDate.
Hoffmann C, Ernst E, Meyer P, 2008. Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune responses. J Clin Microbiol Infect. 708–712.
Karimi K, Wheat LJ, Connolly P. 2002. Diferences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis: 1655–60.
Haskins JL. 2009. Human immunodeficiency virus (HIV) and Mycobacterium tuberculosis: A collaboration to kill. African J Microbiol Res, 3(13), 1029–35.
Lawn SD, Butera ST, Shinnick TM. 2002. Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis. Microbes and infection, 4, 635–46.
Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. 2012. Tuberculosis and HIV co-infection. PLos Pathog, 8(2), 1–5.
Pawlowski A, Jansson M, Skold M, Rottenberg ME, Kallenius G. 2012. Tuberculosis and HIV co-infection. PLos Pathog, 8(2), 1–5.
Dore G, Sazadeuzs J. 2003. Coinfection HIV and hepatitis virus. Australian Society for HIV Medicine.
Dyer JR, Edis RH, French MA. 1998. Enterovirus associated neurological disease in HIV-1 infected man. J Neurovirol. 4(5), 569–71.
Josekuty J, Yeh R, Mathew S, Ene A, Ramessar N, Trinidad J. 2013. Atypical Presentation of West Nile Virus in a newly diagnosed HIV patient in New York. J Clin Microbiol, 51(4), 1307–1311.
CDC, 2010 Japenese Encephalitis. MMWR, 59(1), www. cdc.gov/mwr.
WHO, 2007. Manualfor the Laboratory Diagnosis of Japanese Encephalitis Virus. Available from http://www.who.int/immunization_ monitoring/Manual_lab_diagnosis_JE.
Siong WC, Ching TH, Jong GC, Fang CS, Sin LY, 2008. Dengue infections in HIV patients. Southeast Asian J Trop Med Pub Health, 39(2), 260–68.
The Indonesian Journal of Tropical and Infectious Disease (IJTID) is a scientific peer-reviewed journal freely available to be accessed, downloaded, and used for research. All articles published in the IJTID are licensed under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which is under the following terms:
Attribution ” You must give appropriate credit, link to the license, and indicate if changes were made. You may do so reasonably, but not in any way that suggests the licensor endorses you or your use.
NonCommercial ” You may not use the material for commercial purposes.
ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.
No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
